Neurodegenerative Disorder News and Research

RSS

vTv Therapeutics enrolls first patients in azeliragon Phase 3 trial for treatment of mild Alzheimer's disease

vTv Therapeutics LLC today announced enrollment of the first patients into STEADFAST (Single Trial Evaluating Alzheimer's Disease Following Addition to Symptomatic Therapy), vTv's Phase 3 placebo controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE) for treatment of mild Alzheimer's disease.

19 May 2015

Study could lead to new therapeutic targets for treating Huntington's disease

An international study led by researchers from Université Laval and CHU de Québec-Université Laval has identified significant vascular changes in the brains of people with Huntington's disease. This breakthrough, the details of which are published in the most recent issue of Annals of Neurology, will have significant implications for our understanding of the disease and could open the door to new therapeutic targets for treating this fatal neurodegenerative condition.

17 Apr 2015

Simple blood test could be developed to diagnose Alzheimer's disease, say UCLA researchers

UCLA researchers have provided the first evidence that a simple blood test could be developed to confirm the presence of beta amyloid proteins in the brain, which is a hallmark of Alzheimer's disease.

12 Mar 2015

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Christian Griesinger, director of the NMR-based Structural Biology department at the Max-Planck Institute for Biophysical Chemistry, talks about his research into neurodegenerative diseases using NMR to examine the dynamics of disordered proteins.

From Bruker BioSpin - NMR, EPR and Imaging 23 Feb 2015

Creatine monohydrate fails to slow clinical progression of Parkinson's disease

Treatment with creatine monohydrate for at least 5 years for patients with early and treated Parkinson disease failed to slow clinical progression of the disease, compared with placebo, according to a study in the February 10 issue of JAMA.

11 Feb 2015

TSRI researchers identify enzyme that produces inflammatory lipid molecules in the brain

A team led by scientists at The Scripps Research Institute has identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited neurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that inhibit this enzyme.

13 Jan 2015

New findings may lay groundwork of novel treatment for people with Huntington's disease

By adjusting the levels of a key signaling protein, researchers improved motor function and brain abnormalities in experimental animals with a form of Huntington's disease, a severe neurodegenerative disorder.

5 Jan 2015

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

DSN supports research into possible links between deafness and dementia

A Cheshire charity is set to generate national impact by backing research into possible links between deafness and dementia.

30 Oct 2014

Scientists use innovative exome sequencing strategy to identify new gene associated with ALS

Using an innovative exome sequencing strategy, a team of international scientists led by John Landers, PhD, at the University of Massachusetts Medical School has shown that TUBA4A, the gene encoding the Tubulin Alpha 4A protein, is associated with familial amyotrophic lateral sclerosis (ALS), a fatal neurological disorder also known as Lou Gehrig's Disease.

23 Oct 2014

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease.

21 Oct 2014

Researchers define the process of Parkinson's disease using genetic mouse model

Parkinson's Disease is the second most common neurodegenerative disorder. In Germany alone, almost half a million people are affected. The focus of the disease is the progressive degeneration of dopamine-producing nerve cells in a certain region of the midbrain, the substantia nigra. Misfolded proteins are the cause. Until recently, it was unclear why damage is confined to specific nerve cells.

16 Oct 2014

TyrRS enzyme protects DNA during cellular stress

Scientists at The Scripps Research Institute have found that an enzyme best known for its fundamental role in building proteins has a second major function: to protect DNA during times of cellular stress.

3 Oct 2014

Scientists apply iPS cell technology to Huntington's disease transgenic monkey model

Creating induced pluripotent stem cells or iPS cells allows researchers to establish "disease in a dish" models of conditions ranging from Alzheimer's disease to diabetes.

8 Sep 2014

Depression remains untreated for many Parkinson's disease patients

Depression is known to be a common symptom of Parkinson's disease, but remains untreated for many patients, according to a new study by Northwestern Medicine investigators in collaboration with the National Parkinson's Foundation.

16 Aug 2014

Research reveals structural differences of protein involved in Huntington's disease

Neutron scattering research at the Department of Energy's Oak Ridge National Laboratory has revealed clear structural differences in the normal and pathological forms of a protein involved in Huntington's disease.

17 Jul 2014

Sleep problems in PD patients can worsen in later stages of disease

Up to 70% of Parkinson's disease (PD) patients experience sleep problems that negatively impact their quality of life.

11 Jul 2014

CWRU receives $12.6 million from NIA to identify rare genetic variants that contribute to Alzheimer's

Researchers from Case Western Reserve University School of Medicine are part of a five-university collaboration receiving a $12.6 million, four-year grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to identify rare genetic variants that may either protect against, or contribute to Alzheimer's disease risk.

8 Jul 2014

DBS improves motor and non motor symptoms of patients with early Parkinson's disease

Deep brain stimulation (DBS) has become a well-recognized non-pharmacologic treatment that improves motor symptoms of patients with early and advanced Parkinson's disease.

26 Jun 2014